



ASX RELEASE

Volpara receives FDA clearance for next-generation algorithm and architecture

Wellington, NZ, 29 July 2021: Volpara Health Technologies (“Volpara,” “the Group,” or “the Company”; ASX:VHT), a global health technology software leader providing an integrated breast care platform for the delivery of personalised breast care, has received FDA clearance for the latest version of its key science algorithm, Volpara Imaging Software (VIS 3.2).

VIS 3.2 represents the set of algorithms behind the integrated Volpara Breast Health Platform — a product suite designed to enable earlier detection of breast cancers through improved mammography quality and workflow, volumetric assessment of breast density, and personalised breast care.

The clearance includes Volpara’s updated Open Virtual Appliance (OVA) architecture, which increases image processing security and makes it easier for Volpara to monitor, service, and update software service—a key part of the company’s strategic move to achieve greater scalability and lay the foundations for future new products.

VIS 3.2 improves the overall robustness of the density assessment algorithm, in particular with regard to the incorporation of learnings from artificial intelligence. The clearance also expands the use of VIS 3.2 to additional mammography machines, increasing support for various Giotto and Siemens units, thus extending Volpara’s reach and multi-vendor capabilities.

Dr. Ralph Highnam, Group CEO of Volpara, said: “These new innovations improve the overall security, scalability, robustness, and breadth of our breast health offering. Our objective with each enhancement is the pursuit of our mission—to eliminate advanced-stage breast cancer and save more families from cancer.”

Authorisation & Additional Information

This announcement was authorised by the Board of Volpara Health Technologies Limited.

ENDS

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparahealth.com
t: +64 21 149 0541

Trevor Chappell
WE Communications
WE-AUVolpara@we-worldwide.com
t: +61 407 933 437

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a health technology software company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 39 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020, and has made two significant acquisitions in MRS Systems, Inc. (patient tracking software), and CRA Health, LLC (risk and genetics software). VHT is based in Wellington, New Zealand.

For more information, visit www.volparahealth.com